



Prescribing pearls: A guide to calcium channel blockers (CCBs)

What are calcium channel blockers?

Calcium channel blockers (CCBs) are medications that subdivide into two categories based on their molecular structure:

- **Dihydropyridine (DHP) CCBs** are used to treat hypertension and for prophylaxis of chronic stable angina. Examples include amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine and nimodipine.
- **Non-DHP CCBs**, otherwise known as **rate-limiting CCBs**, can also be used to treat hypertension and angina, but additionally are effective in managing supraventricular tachycardias. There are two non-DHP CCBs: diltiazem and verapamil.

CCBs are well absorbed orally and, as lipophilic molecules, are highly protein-bound in the circulation. Metabolism occurs principally in the liver via the CYP3A4 enzyme, and hepatic first-pass metabolism can be extensive. Following metabolism, elimination is via the kidneys.¹

Mechanisms of action^{2,3}

- When calcium ions (Ca^{2+}) gain entry to a cell, they bind to intracellular calcium-binding proteins, namely troponin and calmodulin in cardiac and smooth muscle respectively, to initiate muscle contraction.
- CCBs inhibit the inward flow of Ca^{2+} through ion channels located in the cell membrane.
- By lowering intracellular Ca^{2+} concentrations, CCBs induce smooth muscle relaxation and, hence, peripheral vasodilation and a reduction in blood pressure (BP).
- In myocardial cells, the consequence of lower Ca^{2+} concentration is reduced activity at the sinoatrial and atrioventricular nodes, allowing treatment of supraventricular tachycardias with non-DHP CCBs.
 - Reduced activity of cardiac myocytes leads to decreased cardiac contractility, reducing oxygen demands of the heart.

Licensed indications of CCBs for hypertension, chronic stable angina and supraventricular tachycardia⁴

CCB	Type of CCB	Hypertension	Angina	Arrhythmias*
Amlodipine	DHP	Yes	Yes	No
Felodipine	DHP	Yes	Yes	No
Lacidipine	DHP	Yes	No	No
Lercanidipine	DHP	Yes	No	No
Nicardipine	DHP	Yes	Yes	No
Nifedipine	DHP	Yes	Yes	No
Nimodipine	DHP	No	No	No
Diltiazem	Non-DHP	Yes	Yes	No [†]
Verapamil	Non-DHP	Yes	Yes	Yes

* Arrhythmias include atrial fibrillation, atrial flutter, SVT prophylaxis, paroxysmal SVT.

[†]Diltiazem is recommended by NICE as an option for treating SVT but this is an unlicensed use.

DHP=dihydropyridine; SVT=supraventricular tachycardia.

Other uses

- **Nimodipine** is licensed for intravenous use in the treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage, and for oral use in prevention of the same.
- **Nicardipine** is licensed as an intravenous infusion for life-threatening hypertension, including in pregnancy (pre-eclampsia) and for postoperative hypertension.
- **Nifedipine immediate-release** is licensed for treatment of Raynaud's syndrome and hiccup in palliative care; an unlicensed use is postponement of premature labour. Avoid using for hypertension and angina.
 - By reducing pulmonary artery pressure, immediate-release nifedipine can be used to treat pulmonary hypertension and high altitude pulmonary oedema (unlicensed).
- Further licensed uses of **verapamil** are: prophylaxis after myocardial infarction where beta-blockers not appropriate, and prophylaxis of cluster headache (initiated under specialist supervision).
- Treatment of chronic anal fissure can be treated topically with 0.2–0.5% **nifedipine** ointment or 2% **diltiazem** cream or ointment for up to 8 weeks. Oral **nifedipine** and **diltiazem** are unlicensed treatments for anal fissure.



Positioning in guidelines

Hypertension

First line: NICE NG136 recommends CCBs as first-line treatment for hypertension in adults who **do not** have type 2 diabetes and:⁵

- are age 55 or over, **or**
- are of Black African or African-Caribbean family origin, of any age.

A thiazide-like diuretic should be used in preference to a CCB if there is evidence of heart failure or a CCB is poorly tolerated.

Second line: CCBs (or thiazide-like diuretics) are second-line antihypertensive treatments (after an ACE inhibitor or ARB) in people with **type 2 diabetes**, and in those without type 2 diabetes who are less than 55 years of age and not of Black African or African-Caribbean family origin). CCBs are also a second-line option for hypertension in people with **type 1 diabetes** (in whom ACEi/ARBs are also recommended first-line).⁶

Third line: If an individual is taking dual therapy with a RAAS blocker and a thiazide-like diuretic and hypertension remains uncontrolled, a CCB is recommended as third-line therapy.⁵

Angina

- NICE CG126 recommends a CCB or beta-blocker as first-line regular treatment for stable angina, with the choice made according to comorbidities, contraindications and the person's preference.⁷

- If beta-blocker monotherapy does not satisfactorily control angina symptoms, a CCB can be substituted or added.

- If a CCB is used in combination with a beta-blocker, choose a DHP CCB. As rate-limiting CCBs, verapamil especially and diltiazem to a lesser extent could precipitate severe bradycardia and heart failure if used with a beta-blocker.

Arrhythmias⁸

- Intravenous verapamil is an option for urgent rate control in acute onset of atrial fibrillation or atrial flutter, if cardioversion is not appropriate and if an intravenous beta-blocker is unsuitable. Avoid verapamil if left ventricular ejection fraction is <40% or if acute heart failure is suspected.
- Oral verapamil or diltiazem (unlicensed use) are alternative options to a beta-blocker for rate control of atrial fibrillation that is not of new onset or which has a reversible cause (and less commonly as an adjunctive treatment for atrial flutter).
 - Diltiazem can be used in combination with a beta-blocker or digoxin if necessary to achieve the target rate control.
- Verapamil and diltiazem can be used to prevent recurrent episodes of paroxysmal supraventricular tachycardia.
- Where urgent treatment of supraventricular tachycardia is necessary, intravenous verapamil can be used if intravenous adenosine is ineffective or contraindicated.

Principal effects

- **BP reduction:** typically by 9.5–13.2 mmHg systolic and 5.9–8.5 mmHg diastolic, with consistent reductions through a 24-hour period.⁹
 - CCBs appear to be more effective as monotherapy than other classes of antihypertensive agent (e.g. ACE inhibitors) in Black people compared with other ethnicities.^{3,10}
 - When used in combination with other antihypertensive agents, CCBs work synergistically, generating a greater antihypertensive effect than the maximal dose of one drug.¹¹
 - DHP CCBs are preferred over non-DHP varieties for treatment of hypertension, as they have the most evidence from clinical trials.¹²
- **Cardiovascular benefits:** through their antihypertensive effects, CCBs reduce the risk of major cardiovascular events, heart failure and all-cause mortality.¹³
 - Superior to other antihypertensives for preventing stroke.¹⁴
 - Inferior to other antihypertensives for preventing heart failure.¹⁴
 - DHP CCBs are particularly effective in reducing

cardiovascular events in the elderly and those with isolated systolic hypertension.¹⁵

- DHP CCBs have been shown to reduce cardiovascular events in people with diabetes,¹⁶ and so are a good second-line option to RAAS-based drugs for treating hypertension.
- Nimodipine has a unique preferential vasodilatory effect on cerebral arteries; thus, its use is confined to preventing and treating vascular spasm following aneurysmal subarachnoid haemorrhage.⁴
- The non-DHP CCBs act preferentially on myocardial cells rather than by peripheral vasodilation. They reduce cardiac oxygen demand, allowing treatment of angina, and inhibit atrioventricular node activity, allowing treatment and prevention of supraventricular tachycardias.³
 - Verapamil has more powerful cardiac effects than diltiazem.
- Both DHP-CCBs and diltiazem are effective (first-line) treatments for vasospastic (Prinzmetal) angina, by relieving coronary vasospasm.^{3,17}
- CCBs are an effective add-on treatment to RAAS blockers for managing albuminuria.¹⁸

**Contraindications, cautions and drug interactions⁴**

	Contraindications	Cautions	Drug interactions
Dihydropyridine CCBs	Cardiac outflow obstruction (e.g. aortic stenosis) Unstable angina Within 1 month of myocardial infarction Cardiogenic shock or uncontrolled heart failure	Elderly (risk of postural hypotension) Sick sinus syndrome (if no pacemaker) Left ventricular dysfunction/HFrEF Hepatic impairment (may need to reduce dose)	Risk of hypotension with other antihypertensive agents Inducers of CYP3A4 (e.g. rifampicin, carbamazepine) can reduce CCB levels; inhibitors of CYP3A4 (e.g. clarithromycin/erythromycin, itraconazole/ketoconazole, ritonavir) can increase levels
Non-dihydropyridine CCBs	Second- or third-degree heart block and sick sinus syndrome (if no pacemaker) Severe bradycardia Aortic stenosis Left ventricular dysfunction/HFrEF and cardiogenic shock	Elderly First-degree atrioventricular block Prolonged PR interval Hepatic impairment	With beta-blocker: avoid use of verapamil, use diltiazem with caution See CYP3A4 interactions above – verapamil and diltiazem are themselves inhibitors of this enzyme

HFrEF=heart failure with reduced ejection fraction.

- If a CCB is needed in individuals with stable heart failure, amlodipine is the drug of choice.¹⁹
- For those who have left ventricular dysfunction/heart failure post-myocardial infarction, CCBs should generally be avoided except amlodipine.⁴
- In people with heart failure with preserved ejection fraction, DHP CCBs, notably amlodipine, can be used.

Prescribing in pregnancy

In general, CCBs should be avoided if possible in pregnancy and breastfeeding unless benefits are judged to outweigh risks. Nifedipine is considered a safe option in pregnancy if labetalol is unsuitable, or in combination with labetalol if necessary, with methyldopa as a further option. Check to see which brands of nifedipine are indicated for use in pregnancy. Nifedipine and amlodipine, if previously used to control BP, can be used in the postnatal period.²⁰

- In women with chronic hypertension, the choice of antihypertensive medication should ideally be optimised pre-conception, switching, if necessary, from ACEi/ARBs and thiazide-like diuretics, which could predispose to congenital abnormalities, to labetalol and nifedipine.

Adverse effects**DHP CCBs**

Common side-effects, most of which are the result of vasodilation, include:

- Peripheral oedema – ankle swelling.
- Headache.
- Flushing.
- Dizziness – postural hypotension.
- Palpitations – tachycardia.
- Nausea and gastrointestinal reflux (relaxation of oesophageal sphincter smooth muscle).

Peripheral oedema, and other side-effects, are more likely to occur with higher doses. Strategies to reduce CCB-induced ankle swelling include:¹⁸

- Reduce the dose of DHP CCB.
- Switch to a more lipophilic DHP CCB (e.g. lercanidipine, lacidipine).

- Switch to a non-DHP CCB.
- Employ combination antihypertensive therapy – diuretic therapy or ACEi/ARB (shown to reduce peripheral oedema in combination with CCB).²¹

Non-DHP CCBs

The previous vasodilatory side-effects are typically less marked with non-DHP CCBs. Bradycardia occurs rather than tachycardia and this, together with the drugs' negative inotropic action, can lead to hypotension and dizziness. Other adverse effects include:

- Constipation – especially with verapamil.
- Atrioventricular block, conduction disorders (e.g. QT prolongation).
- Heart failure.
- Rashes – erythema multiforme, Stevens–Johnson syndrome (severe).



Dosing schedules and formulations⁴

Drug	Dosing schedule	Available formulations
Amlodipine	5–10 mg <i>od</i> , initially 5 mg <i>od</i>	2.5 mg, 5 mg, 10 mg tablets 5 mg/5 mL oral solution or suspension 10 mg/5 mL oral solution
Felodipine	2.5–10 mg <i>od</i> , initially 5 mg <i>od</i> 2.5 mg <i>od</i> in elderly	2.5 mg, 5 mg, 10 mg modified-release tablets
Lacidipine	2–6 mg <i>od</i> , initially 2 mg <i>od</i>	2 mg, 4 mg tablets
Lercanidipine hydrochloride	10–20 mg <i>od</i> , initially 10 mg <i>od</i>	10 mg, 20 mg tablets
Nicardipine hydrochloride	20–30 mg <i>tds</i> Intravenous infusion for life-threatening and postoperative hypertension	20 mg, 30 mg capsules 10 mg/10 mL and 25 mg/10 mL solutions for intravenous infusion
Nifedipine	Immediate-release form: 5–20 mg <i>tds</i> , for Raynaud's syndrome, hiccup Modified-release form: 20–90 mg daily as single or twice daily dosing depending on brand, for hypertension and angina	5 mg, 10 mg immediate-release tablets 10 mg, 20 mg, 30 mg, 40 mg, 60 mg modified-release tablets/capsules 20 mg/mL oral drops
Nimodipine	60 mg every 4 hours for 21 days, for prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage Intravenous infusion for at least 5 days, for treatment of the same	30 mg tablets 0.02% solution for intravenous infusion
Diltiazem hydrochloride	180–360 mg daily for hypertension, 180–500 mg daily for angina. Initial dose, dosing frequency and dose reductions for elderly are brand-dependent	60 mg, 90 mg, 120 mg modified-release tablets 90 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg modified-release capsules
Verapamil hydrochloride	Immediate-release form: 240–480 mg daily in 2–3 divided doses for hypertension; 80–120 mg <i>tds</i> for angina; 40–120 mg <i>tds</i> for supraventricular tachycardia (or 5–10 mg by slow intravenous injection if urgent) Modified-release form: 120–240 mg daily initially, up to 480 mg daily, usually in 2 divided doses. Initial dose and dosing frequency are brand-dependent	40 mg, 80 mg, 120 mg, 160 mg immediate-release tablets 120 mg, 240 mg modified-release tablets 40 mg/5 mL oral solution 5 mg/2 mL solution for intravenous injection

It is important to be aware that there is variation both in the licensed indications and doses within an indication of different formulations of the same drug, hence the need to check individual generic and brand indications and dosing regimens.

CCBs in combined preparations

- Amlodipine + valsartan
- Amlodipine + olmesartan
- Amlodipine + olmesartan + hydrochlorothiazide
- Amlodipine + perindopril erbumine
- Felodipine + ramipril

Initiating and monitoring¹

- Generally start CCBs at low dose, especially in the older person, and titrate upwards as required, monitoring for side-effects.
- Check BP and pulse before starting a CCB, and monitor after initiation.
- Response of BP or symptoms of angina will inform on efficacy.
- In the case of verapamil and diltiazem, LFTs should be monitored. When they are used for treating arrhythmias, ECG monitoring is appropriate.



Prescribing tips

- When prescribing modified-release preparations of CCBs, specify the brand. Different brands may generate different clinical responses.
- Be aware that withdrawal of a CCB may worsen or unmask myocardial ischaemia.
- Avoid use of beta-blockers with verapamil and use them cautiously with diltiazem. There is a risk of severe bradycardia and triggering of heart failure.
- If eGFR is $<30 \text{ mL/min/1.73 m}^2$, check recommendations for specific drugs (and brands).
- Consider dose reduction of CCB for people with hepatic impairment.
- In general, choose a long-acting DHP CCB such as amlodipine for hypertension, and also for angina if a beta-blocker is being used. For angina not treated with a beta-blocker, a non-DHP CCB is appropriate.
- Immediate-release nifedipine is not recommended for treating hypertension and angina because it can cause a rapid fall in BP (rather than a sustained reduction) with reflex tachycardia – hypotension and myocardial ischaemia may result.

Calcium channel blockers: Key summary table

Position in treating hypertension	First-line if ≥ 55 years old without type 2 diabetes First-line any age if Black African/African-Caribbean without type 2 diabetes Second-line to ACEi/ARB in type 2 diabetes , or if <55 years old and not Black ethnicity Third-line if already taking ACEi/ARB and thiazide-like diuretic
Position in treating angina	Alternative to beta-blockers as first-line prophylaxis of stable angina Can use DHP CCBs in combination with beta-blocker. With beta-blocker, avoid use of verapamil, use diltiazem with caution
Position in treating atrial arrhythmias	Non-DHP CCBs verapamil and (unlicensed) diltiazem are alternative options to a beta-blocker for atrial fibrillation rate control and in the prevention of paroxysmal supraventricular tachycardias Intravenous verapamil is an option for urgent rate control in atrial fibrillation or atrial flutter
Other uses	Immediate-release nifedipine for Raynaud's syndrome, hiccup in palliative care Verapamil for prophylaxis of cluster headaches, prophylaxis after myocardial infarction when beta-blocker unsuitable Nimodipine intravenous following subarachnoid haemorrhage Nicardipine intravenous for life-threatening hypertension Nifedipine and diltiazem topically for chronic anal fissure
Contraindications	Aortic stenosis, unstable angina, uncontrolled heart failure Non-DHP CCBs: second/third-degree heart block, sick sinus syndrome, severe bradycardia, heart failure with reduced ejection fraction, left ventricular dysfunction
Cautions	Hepatic impairment, elderly DHP CCBs: heart failure with reduced ejection fraction, left ventricular dysfunction, sick sinus syndrome Non-DHP CCBs: first-degree atrioventricular block
Side-effects	Ankle swelling, headaches, flushing, dizziness DHP CCBs: tachycardia Non-DHP CCBs: bradycardia, atrioventricular block/conduction disorders, heart failure, constipation (verapamil)
Starting treatment	Start low dose, especially in older person, and titrate dose upward as needed
Monitoring	Blood pressure, pulse. For non-DHP CCBs, monitor LFTs, ECG monitoring if used for arrhythmias

Author: David Morris, Retired GP and Specialist Doctor in Diabetes, Undergraduate Clinical Tutor, Keele University.

Citation: Morris D (2025) Prescribing pearls: A guide to calcium channel blockers (CCBs). *Diabetes & Primary Care* 27: [Early view publication]

See also

- [Prescribing pearls: A guide to ACE inhibitors](#)
- [Prescribing pearls: A guide to ARBs](#)

References can be found in the HTML version of this article.

[Click here to access.](#)